The diagnostic importance of biomarkers of angio-genesis and inflammation at patients with prostate diseases

Bibliography:
1. Lyubimova NV, Kushlinsky NE, Strogova EV, Gorilovsky LM, Lahno IG. Clinical significance of total and free prostate specific antigen in prostate cancer. Clinical laboratory diagnostics 1998; (2): 6-9
2. Shariat SF, Semjonow A, Lilja Н, Savage С, Vickers AJ, Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncologica 2011; (50): 61-75
3. Carver BS, Bozeman CB, Williams BJ, Venable DD. The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. Journal of Urology 2003; (169): 89-91
4. Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. ВМС Family Practice 2002; 24 (3):19
5. Bessede T, Malavaud B. The new biomarkers of prostate cancer. Prog Urol 2011; (21): 3-7
6. Pallares J, Rojo F, Iriarte J, Morote J, Armadans LI, et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 2006; 21 (8): 57-65
7. Kubisz P, Chud P, Stasko J. et al. Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus. Act Diabetol 2010; 47 (2): 19-24
8. Zachary I, Mathur A, Yla-Herttuala S, et al. Vascular protection: a novel nonangiogenic cardiovascular role for VEGF. Arterioscler Thromb Vase Biol 2000; (20): 12-20
9. Gavrilenko TS, Ryzhkov NA, Parkhomenko AN. Vascular endothelial growth factor in the clinic of internal disease and its pathogenetic significance. Ukrainian cardiology journal 2011; (4): 87-95
10. Lebedev SV, Karasev AV, et al. Cell therapy of critical limb ischemia (problems and prospects). Vestnik of the Russian Academy of Medical Sciences 2013; (3): 34-44
11. Bruunsgaard Н. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur Cytokine Netw 2002; 13 (4): 389-391
12. Mann JR, DuBois RN. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 2004; (10): 145-152
13. Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer. II: Role of chronic inflammation and cytokine polymorphisms in the pathogenesis of gastrointestinal malignancy. American Journal of Physiology — Gastrointestinal and Liver Physiology 2004; (286): 515-520
14. Whitcomb DC. Inflammation and cancer. V: chronic pancreatitis and pancreatic cancer. American Journal of Physiology — Gastrointestinal and Liver Physiology. 2004; (287): 315-319
15. Askling J, Grunewald J, Eklund A, et al. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999; (160): 1668-1672
16. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N- (4-hydroxybutyl) — nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; (60): 55-56
17. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 1996; (16): 46-46
18. Mao JT, Cui X, Reckamp K, et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 2005; (7): 30-39
19. Lin DT, Subbaramaiah K, Shah JP, et al. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; (24): 792-799
20. Lin EY, Pollard JW. Macrophages: modulators of breast cancer progression. Novartis Found Symp2004; (256): 158-168. 21. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995; (4): 447-451
22. Perky L. Epidemiology of cancer of the penis. Recent Results Cancer Res 1977; (60): 97-109
23. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; (172): 6-11
24. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2004; (26): 1170-1181
25. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010; 55: 1169-1177
26. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; (21): 505-515
27. Yeap BB, Alfonso H, Chubb SA, et al. In older men, higher plasma testosterone or dihydrotestosterone is an independent predictor for reduced incidence of stroke but not myocardial infarction. J Clin Endocrinol Metab 2014; 99 (12): 565-573
28. Shores MM, Biggs ML, Arnold AM, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab 2014; 99 (6): 61-68
29. Shores MM, Arnold AM, Biggs ML, et al. Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study. Clin Endocrinol 2014; 81 (5): 746-753
30. Garni AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49 (4): 403-414
31. Blankfield RP Androgen deprivation therapy for prostate cancer and cardiovascular death. JAMA 2012; (307): 1252-1253
32. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008; (54): 816-823
33. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate specific antigen in a cjmmunity based population of healthy men: establishment of age specific reference ranges. JAMA 1993; (270): 860-864
34. Zakharova NB, Varaksin NA, Tereshkina NE, et al. Concentration of growth factor vascular endothelium in the blood of healthy individuals varies with age. News Vector Best 2014; 71 (1): 11-15.